Ona Therapeutics
Founded 2019 · 9 known investors
Ona Therapeutics is a biotechnology company developing first-in-class antibody drug conjugates (ADCs) and antibody therapies targeting the molecular biology of treatment-refractory advanced cancers. Spun out of ICREA and IRB, it focuses on precision therapeutics for patients with advanced solid tumors such as breast cancer who have no remaining treatment options.
BiotechHealthtech
Investors · 9
Fund+Leuven · $5.5M – $16.5M
KorysHalle · $5.4M
Mérieux Equity PartnersParis · $3.2M – $86M
Ysios CapitalBarcelona · $5.4M – $21.6M
Alta Life SciencesreportedBarcelona
Asabys Partnersreported · 2 sourcesMadrid
BpifrancereportedParis, Ile-De-France · $270K
CDTIreportedMadrid
Columbus Venture PartnersreportedValencia
Funding
SEC filings, press & company announcements$86.6M disclosed across 1 round · 2026
- $86.6MSeries BJun 2026 · 4 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series Bfiercebiotech.com · Aug 2026Frequently asked questions
- What does Ona Therapeutics do?
- Ona Therapeutics is a biotechnology company developing first-in-class antibody drug conjugates (ADCs) and antibody therapies targeting the molecular biology of treatment-refractory advanced cancers. Spun out of ICREA and IRB, it focuses on precision therapeutics for patients with advanced solid tumors such as breast cancer who have no remaining treatment options.
- Who are Ona Therapeutics's investors?
- Ona Therapeutics's investors include Fund+, Korys, Mérieux Equity Partners, Ysios Capital, Alta Life Sciences, Asabys Partners, Bpifrance, CDTI and 1 more.
- How much funding has Ona Therapeutics raised?
- Ona Therapeutics has disclosed $86.6M raised across 1 round.